Zosuquidar hydrochloride
SIGMA/SML1044 - ≥98% (HPLC)
Synonym: (2R)
CAS Number: 167354-41-8 (free base)
Empirical Formula (Hill Notation): C32H31F2N3O2 · xHCl
Molecular Weight: 527.60 (free base basis)
Linear Formula: C32H31F2N3O2 · xHCl
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to beige |
| form | powder |
| InChI | 1S/C32H31F2N3O2.ClH/c33-3 |
| InChI key | VQJFFWJUYDGTQZ-FCNWNIDBSA |
| Quality Level | 100 ![]() |
| SMILES string | O[C@@H](COC1=C(C=CC=N2)C2 |
| solubility | H2O: 4 mg/mL, clear (warmed) |
| storage condition | desiccated |
| storage temp. | −20°C |
| Biochem/physiol Actions: | Zosuqidar is a potent inhibitor of P-glycoprotein (P-gp, MDR1) a transporter protein that is a key modulator of cellular drug efflux. |
| Biochem/physiol Actions: | Zosuqidar is a potent inhibitor of P-glycoprotein (P-gp, MDR1) a transporter protein that is a key modulator of cellular drug efflux. Zosuquidar sensitizes AML, and other cancer cell lines to cytotoxic drugs. |
| Features and Benefits: | This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm . |
| Packaging: | 5 mg in glass bottle |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H315 - H319 - H335 |
| Precautionary statements | P261 - P264 - P271 - P280 - P302 + P352 - P305 + P351 + P338 |
| Hazard Codes | Xi |
| Risk Statements | 36/37/38 |
| Safety Statements | 26 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | −20°C |
| UNSPSC | 12161501 |


